• Reliq Health Technologies has signed contracts with three physician practices in Texas
  • Reliq will provide its iUGO Care platform to their chronic disease patients
  • The average revenue from these contracts will be US$65 per patient per month
  • Reliq Health Technologies specializes in developing Software-as-a-Service solutions for remote patient monitoring, telemedicine, and care collaboration
  • iUGO Care provides real-time access to remote patient monitoring data
  • Reliq Health Technologies Inc. (RHT) opened trading at C$0.445 per share

Reliq Health Technologies (RHT) has signed contracts with three physician practices to provide its iUGO Care platform to their patients.

“We are very pleased to be adding three new US physician practices to our iUGO Care platform,” said Dr. Lisa Crossley, CEO of Reliq Health Technologies, Inc.

“The average revenue from these contracts will be US$65 per patient per month. All three of these new clients will go live this month. Onboarding with all clients is proceeding per the guidance we have provided for 2021, and we remain on track to exit December 2021 at a run rate of $2,000,000 per month in revenue. We expect to work through our backlog of over 200,000 patients in the next 18-24 months as the healthcare sector continues its recovery from the global pandemic.”

Reliq Health Technologies is a rapidly growing global telemedicine that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market. Reliq’s powerful iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive high-quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery.

iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits.

Reliq Health Technologies Inc. (RHT) opened trading at C$0.445 per share.

More From The Market Online

Canadian biotech stock investigates potential weight loss drugs

FSD Pharma Inc. (CSE:HUGE) is expanding its pipeline into metabolic and related disorders including weight loss and liver health.
The Market Online Video

Emerging opportunity in a growing, high-value dermatological market

Kane Biotech (TSXV:KNE) engages in the development and commercialization of products that prevent and remove microbial biofilms.